Late-stage clinical drug platform company Annovis Bio, Inc. (ANVS), Monday announced the pricing of 5.25 million common stock and warrants to purchase an equal number of shares at a combined price of $4 per share, amounting to a total of $21 million.
The proceeds would be primarily utilized for continued clinical development of the company's lead compound Buntanetap, as well as other corporate-related purposes.
The offering is estimated to close on February 4.
In the pre-market hours, Annovis's stock is moving down 17.66 percent, to $4.01 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.